• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

局部晚期宫颈癌的新辅助化疗

Neoadjuvant chemotherapy for locally advanced cervical cancer.

作者信息

Iwata Takashi, Miyauchi Azumi, Suga Yukako, Nishio Hiroshi, Nakamura Masaru, Ohno Akiko, Hirao Nobumaru, Morisada Tohru, Tanaka Kyoko, Ueyama Hiroki, Watari Hidemichi, Aoki Daisuke

机构信息

1Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan;

2Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Hokkaido, Japan.

出版信息

Chin J Cancer Res. 2016 Apr;28(2):235-40. doi: 10.21147/j.issn.1000-9604.2016.02.13.

DOI:10.21147/j.issn.1000-9604.2016.02.13
PMID:27199522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4865617/
Abstract

Neoadjuvant chemotherapy followed by surgery (NCS) has not been fully evaluated clinically. Currently, the main regimen of neoadjuvant chemotherapy (NAC) used in NCS includes cisplatin. The antitumor effects of NAC reduce lymph node metastasis and the tumor diameter in patients prior to surgery, and this can reduce the number of high risk patients who require postoperative radiation therapy. Many randomized controlled trials (RCTs) have examined the long-term prognosis of NCS compared to primary surgery, but the utility of NCS remains uncertain. The advent of concurrent chemoradiotherapy (CCRT) has markedly improved the outcome of radiotherapy (RT), and CCRT is now used as a standard method in many cases of advanced bulky cervical cancer. NCS gives a better treatment outcome than radiation therapy alone, but it is important to verify that NCS gives a similar or better outcome compared to CCRT.

摘要

新辅助化疗后手术(NCS)尚未在临床上得到充分评估。目前,NCS中使用的新辅助化疗(NAC)的主要方案包括顺铂。NAC的抗肿瘤作用可减少患者术前的淋巴结转移和肿瘤直径,这可以减少需要术后放疗的高危患者数量。许多随机对照试验(RCT)已经研究了NCS与初次手术相比的长期预后,但NCS的效用仍不确定。同步放化疗(CCRT)的出现显著改善了放疗(RT)的效果,CCRT现在在许多晚期巨大宫颈癌病例中被用作标准方法。NCS比单纯放疗有更好的治疗效果,但重要的是要验证NCS与CCRT相比是否有相似或更好的效果。

相似文献

1
Neoadjuvant chemotherapy for locally advanced cervical cancer.局部晚期宫颈癌的新辅助化疗
Chin J Cancer Res. 2016 Apr;28(2):235-40. doi: 10.21147/j.issn.1000-9604.2016.02.13.
2
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.根治性子宫切除术联合放化疗与单纯根治性子宫切除术治疗局部晚期宫颈癌的疗效比较
Cochrane Database Syst Rev. 2022 Aug 22;8(8):CD010260. doi: 10.1002/14651858.CD010260.pub3.
3
Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.对局部晚期宫颈癌女性患者进行子宫切除术并辅以放疗或化疗或两者联合治疗。
Cochrane Database Syst Rev. 2015 Apr 7(4):CD010260. doi: 10.1002/14651858.CD010260.pub2.
4
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.局部晚期宫颈癌同步放化疗后的辅助化疗。
Cochrane Database Syst Rev. 2014 Dec 3;2014(12):CD010401. doi: 10.1002/14651858.CD010401.pub2.
5
Neoadjuvant chemotherapy for locally advanced cervix cancer.局部晚期宫颈癌的新辅助化疗
Cochrane Database Syst Rev. 2004;2004(2):CD001774. doi: 10.1002/14651858.CD001774.pub2.
6
Debulking hysterectomy followed by chemoradiotherapy versus chemoradiotherapy for FIGO stage (2019) IB3/II cervical cancer.FIGO 分期(2019)IB3/II 期宫颈癌行肿瘤细胞减灭术联合放化疗与单纯放化疗的比较。
Cochrane Database Syst Rev. 2022 Sep 16;9(9):CD012246. doi: 10.1002/14651858.CD012246.pub2.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Chemotherapy for advanced gastric cancer.晚期胃癌的化疗
Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4.
9
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.针对接受根治性手术的直肠癌患者的术后辅助化疗。
Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2.
10
Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.局部晚期头颈部鳞状细胞癌:当前治疗方案的系统评价和贝叶斯网络荟萃分析。
Oral Oncol. 2018 May;80:40-51. doi: 10.1016/j.oraloncology.2018.03.001. Epub 2018 Mar 27.

引用本文的文献

1
Chemo-radiotherapy after neoadjuvant chemotherapy and radical hysterectomy in women with stage IB-IIB cervical cancer: Do we need to change the therapeutic approach? A cohort study.IB-IIB期宫颈癌女性新辅助化疗及根治性子宫切除术后的放化疗:我们是否需要改变治疗方法?一项队列研究。
Surg Pract Sci. 2025 Apr 28;21:100284. doi: 10.1016/j.sipas.2025.100284. eCollection 2025 Jun.
2
Management of Bulky Tumors in Cervical Cancer: Limits of the Surgical Approach.宫颈癌巨大肿瘤的管理:手术方法的局限性
J Clin Med. 2025 Feb 10;14(4):1142. doi: 10.3390/jcm14041142.
3
High Expression of Vascular Endothelial Growth Factor, Ki-67, and Protein 53 are Risk Factors for Poor Response of Paclitaxel-Carboplatin Neoadjuvant Chemotherapy in Stadium IB3, IIA2, and IIB Cervical Cancer.血管内皮生长因子、Ki-67 和蛋白 53 高表达是紫杉醇-卡铂新辅助化疗在 IB3、IIA2 和 IIB 期宫颈癌中疗效不佳的危险因素。
Asian Pac J Cancer Prev. 2024 Aug 1;25(8):2625-2631. doi: 10.31557/APJCP.2024.25.8.2625.
4
Decreasing expression of HIF-1α, VEGF-A, and Ki67 with efficacy of neoadjuvant therapy in locally advanced cervical cancer.新辅助治疗局部晚期宫颈癌的疗效与 HIF-1α、VEGF-A 和 Ki67 表达的降低有关。
Medicine (Baltimore). 2023 May 19;102(20):e33820. doi: 10.1097/MD.0000000000033820.
5
Megestrol acetate dispersible tablets with a 5-HT3 receptor antagonist and dexamethasone 5-HT3 receptor antagonist plus dexamethasone, can better control chemotherapy-induced nausea and vomiting: a randomized controlled study.醋酸甲地孕酮分散片联合5-羟色胺3(5-HT3)受体拮抗剂及地塞米松,5-HT3受体拮抗剂加地塞米松,能更好地控制化疗引起的恶心和呕吐:一项随机对照研究。
Ann Transl Med. 2022 Oct;10(20):1124. doi: 10.21037/atm-22-4809.
6
Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review.2018FIGO 期 IIIC 宫颈癌的治疗策略和预后因素:综述。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221086403. doi: 10.1177/15330338221086403.
7
Paclitaxel Plus Platinum Neoadjuvant Chemotherapy Followed by Surgery Primary Surgery in Locally Advanced Cervical Cancer-A Propensity Score Matching Analysis.紫杉醇联合铂类新辅助化疗后手术治疗局部晚期宫颈癌的初次手术——倾向评分匹配分析
Front Oncol. 2020 Dec 7;10:604308. doi: 10.3389/fonc.2020.604308. eCollection 2020.
8
Application of transrectal ultrasound in guiding interstitial brachytherapy for advanced cervical cancer.经直肠超声在晚期宫颈癌组织间近距离治疗中的应用。
J Contemp Brachytherapy. 2020 Aug;12(4):375-382. doi: 10.5114/jcb.2020.98118. Epub 2020 Aug 21.
9
Ginsenoside Rh2 inhibits HeLa cell energy metabolism and induces apoptosis by upregulating voltage‑dependent anion channel 1.人参皂苷Rh2抑制HeLa细胞能量代谢并通过上调电压依赖性阴离子通道1诱导细胞凋亡。
Int J Mol Med. 2020 Nov;46(5):1695-1706. doi: 10.3892/ijmm.2020.4725. Epub 2020 Sep 14.
10
Expression of HIF-1α is a predictive marker of the efficacy of neoadjuvant chemotherapy for locally advanced cervical cancer.缺氧诱导因子-1α(HIF-1α)的表达是局部晚期宫颈癌新辅助化疗疗效的预测标志物。
Oncol Lett. 2020 Jul;20(1):841-849. doi: 10.3892/ol.2020.11596. Epub 2020 May 7.

本文引用的文献

1
The efficacy of neoadjuvant chemotherapy in different histological types of cervical cancer.新辅助化疗在不同组织学类型宫颈癌中的疗效。
Gynecol Oncol. 2014 Aug;134(2):419-25. doi: 10.1016/j.ygyno.2014.06.001. Epub 2014 Jun 8.
2
A metabolomics approach for predicting the response to neoadjuvant chemotherapy in cervical cancer patients.一种用于预测宫颈癌患者新辅助化疗反应的代谢组学方法。
Mol Biosyst. 2014 Aug;10(8):2126-33. doi: 10.1039/c4mb00054d.
3
Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy.接受新辅助化疗后行根治性子宫切除术的宫颈巨大鳞状细胞癌患者的预后因素分析。
Int J Clin Oncol. 2015 Apr;20(2):345-50. doi: 10.1007/s10147-014-0702-6. Epub 2014 May 14.
4
Detection of cell apoptosis in pelvic lymph nodes of patients with cervical cancer after neoadjuvant chemotherapy.新辅助化疗后宫颈癌患者盆腔淋巴结中细胞凋亡的检测
J Int Med Res. 2014 Jun;42(3):641-50. doi: 10.1177/0300060513506328. Epub 2014 Mar 20.
5
Improved survival with bevacizumab in advanced cervical cancer.贝伐珠单抗治疗晚期宫颈癌可提高生存率。
N Engl J Med. 2014 Feb 20;370(8):734-43. doi: 10.1056/NEJMoa1309748.
6
Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102).IB2、IIA2 和 IIB 期宫颈癌新辅助化疗加根治性手术与单纯根治性手术的 III 期随机对照临床试验:日本临床肿瘤学组研究(JCOG0102)。
Br J Cancer. 2013 May 28;108(10):1957-63. doi: 10.1038/bjc.2013.179. Epub 2013 May 2.
7
Platinum derivatives during pregnancy in cervical cancer: a systematic review and meta-analysis.妊娠期宫颈癌铂类衍生物治疗:系统评价和荟萃分析。
Obstet Gynecol. 2013 Feb;121(2 Pt 1):337-343. doi: 10.1097/AOG.0b013e31827c5822.
8
Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.新辅助化疗联合手术与单纯手术治疗宫颈癌的比较
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD007406. doi: 10.1002/14651858.CD007406.pub3.
9
Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis.国际协作荟萃分析:新辅助化疗在 FIGO 分期 IB1 至 IIA 期宫颈癌患者中的疗效。
Eur J Surg Oncol. 2013 Feb;39(2):115-24. doi: 10.1016/j.ejso.2012.09.003. Epub 2012 Oct 18.
10
Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer.局部晚期宫颈癌新辅助化疗加根治性手术加化疗。
Gynecol Oncol. 2012 Nov;127(2):290-6. doi: 10.1016/j.ygyno.2012.07.104. Epub 2012 Jul 20.